A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers

NCT04983368 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment
Alzheimer's Disease

Interventions

DRUG: Xanamem® 5 mg
DRUG: Placebo
DRUG: Xanamem® 10 mg

Sponsor

Actinogen Medical

Collaborators

[object Object]